Recent news on Candesartan Cilexetil

Actos drives growth at Takeda but Januvia threat is hovering  -  May 11, 2007
Pharma Times (subscription),Blood pressure drug Blopress (candesartan cilexetil) posted a 8% increase in sales to 206.2 billion yen, though gastrointestinal drug Takepron

Atacand HCT Medicine - Uses, Dosage & Side Effects  -  Apr 18, 2007
American Chronicle,Therapy with any combination of candesartan cilexetil and hydrochlorothiazide will be associated with both sets of dose-independent side effects.

Sales strong for Takeda but pressure to expand is on  -  Feb 1, 2007
Pharma Times (subscription),Blood pressure drug Blopress (candesartan cilexetil) posted a 5.7% increase in sales to 157.1 billion yen, though gastrointestinal drug Takepron

Incidence of hypertension reduced with early intervention  Oct 17, 2006
..." We chose to administer a low dose of Candesartan cilexetil ( Atacand/Ratacand ) because it has qualities that suggest it changes characteristics of the blood ... -Xagena.it, The results of CASE-J study, the first large-scale clinical study ...  Oct 19, 2006
This is the first large-scale outcome study in Japan comparing Blopress®, (generic name: candesartan cilexetil), angiotensin receptor blocker and Amlodipine ... -PipelineReview.com (press release), Incidence of hypertension reduced with early intervention  Aug 25, 2006
..." We chose to administer a low dose of the ARB medication Candesartan cilexetil ( Atacand/Ratacand ) because it has qualities that suggest it changes ... -Xagena.it

Benefits of Candesartan added to ACE inhibitor in inhibition of ...  Sep 2, 2006
...with non-diabetic renal disease. Candesartan cilexetil is an angiotensin II receptor antagonist ( ARB ). The study involved 90 hypertensive ... -Xagena.it

Incidence of hypertension reduced with early intervention  Aug 25, 2006
..." We chose to administer a low dose of the ARB medication Candesartan cilexetil ( Atacand/Ratacand ) because it has qualities that suggest it changes ... -Xagena.it

Incidence of Atrial Fibrillation Significantly Reduced by ...  Jul 5, 2006
Atrial fibrillation is associated with a decline in cardiac function and worsening of heart failure symptoms including reduction in exercise capacity as well ... -DG News

Incidence Of Atrial Fibrillation Significantly Reduced By ...  Jul 16, 2006
Osaka, Japan - New data published in the July issue of the American Heart Journal show that candesartan cilexetil (candesartan) is the first angiotensin ... -Medical News Today

Updating European Guidelines for the Management of Hypertension  Jul 17, 2006
J Am Coll Cardiol. 2004;44:1175-1180. Abstract. Schrader J, Luders S, Kulschewski A, et al; Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. ... -Medscape (subscription)

Incidence of Atrial Fibrillation Significantly Reduced by ...  Jul 10, 2006
New data published in the July issue of the American Heart Journal show that candesartan cilexetil (candesartan) is the first angiotensin receptor blocker (ARB ... -PharmaLive.com

Incidence Of Atrial Fibrillation Significantly Reduced By Atacand ...  Jul 10, 2006
New data published in the American Heart Journal show that Atacand® (candesartan cilexetil) is the first angiotensin receptor blocker (ARB) to significantly ... -Medical News Today

Incidence Of Atrial Fibrillation Significantly Reduced By Atacand ...  Jul 10, 2006
OSAKA, Japan | Jul 10, 2006 | New data published in the American Heart Journal show that Atacand® (candesartan cilexetil) is the first angiotensin receptor ... -PipelineReview.com



Combined Use of ATACAND(R) (candesartan cilexetil) and ACE ...  May 4, 2006
In 2005, the committee voted unanimously to recommend approval for use of ATACAND(R) (candesartan cilexetil) in combination with ACE inhibitors for the ... - Finanzen.net

Combined Use of ATACAND(R) (candesartan cilexetil) and ACE ...  May 4, 2006
...review of the CHARM-Added trial." In 2005, the committee voted unanimously to recommend approval for use of ATACAND(R) (candesartan cilexetil) in combination ... - PR Newswire

Novel Study Published In New England Journal Of Medicine Evaluates ...  Apr 21, 2006
...four-year trial, there was a significant (15.6 percent) relative risk reduction in the group treated with ATACAND(R) (candesartan cilexetil), compared with the ... - Medical News Today

AstraZeneca's ATACAND Effective In Treating Patients With ...  Apr 20, 2006
...patients with prehypertension. The patients were given ATACAND or candesartan cilexetil in dosage of 16 mg once daily. Blood pressure ... - Trading Markets





Novel TROPHY Study Is First to Evaluate Effects of Pharmacological ...  Mar 14, 2006
...end point of development of hypertension, there was a 15.6% relative risk reduction in the group treated with ATACAND(R) (candesartan cilexetil) compared with ... - Finanzen.net

Hypertension reduced with early intervention  Mar 19, 2006
..."We chose to administer a low dose of the ARB medication candesartan cilexetil because it has qualities that suggest it changes characteristics of the blood ... - News-Medical.net

Early blood pressure treatment with candesartan may postpone ...  Mar 21, 2006
Hypertension or TROPHY study, was funded by AstraZeneca, the pharmaceutical company that makes candesartan and sells it as ATACAND (candesartan cilexetil). ... - News-Medical.net

High Blood Pressure – The sooner treated with Medication the ...  Mar 14, 2006
...trial called TROPHY. Funding for the trial came from AstraZeneca who are the makers of ATACAND (candesartan cilexetil). The trial ... - Best Syndication

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional